[go: up one dir, main page]

WO2000077218A1 - Vaccine for newcastle disease virus - Google Patents

Vaccine for newcastle disease virus Download PDF

Info

Publication number
WO2000077218A1
WO2000077218A1 PCT/IB2000/000748 IB0000748W WO0077218A1 WO 2000077218 A1 WO2000077218 A1 WO 2000077218A1 IB 0000748 W IB0000748 W IB 0000748W WO 0077218 A1 WO0077218 A1 WO 0077218A1
Authority
WO
WIPO (PCT)
Prior art keywords
ndv
virulent
vaccine
dna
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/000748
Other languages
French (fr)
Inventor
Austen Shawn Cohen
Gerrit Johannes Viljoen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agricultural Research Council
Original Assignee
Agricultural Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agricultural Research Council filed Critical Agricultural Research Council
Priority to AU46060/00A priority Critical patent/AU4606000A/en
Publication of WO2000077218A1 publication Critical patent/WO2000077218A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to a circular polynudeotide vaccine, capable of expressing a fusion (F) protein of a virulent strain of Newcastle disease virus (NDV).
  • This invention further relates to recombinant DNA and a gene encoding such F protein, and bioprecursors and products thereof.
  • a known DNA based vaccine is described in: PROTECTION OF CHICKENS FROM NEWCASTLE DISEASE BY VACCINATION WITH A LINEAR PLASMA DNA EXPRESSING THE F PROTEIN OF NEWCASTLE DISEASE VIRUS; Masashi Sakaguchi, Hideki Nakamura, Kengo Sonoda, Fukusaburo Hamada and Kanji Hirai, Vaccine, Volume 14, Number 8, pp 747 - 752, 1996.
  • a plasmid DNA vaccine comprising plasmid DNA expressing the F protein of an avirulent strain of Newcastle disease virus (NDV- F). Birds were infected with either circular or linearised plasmid DNA. The article concludes that birds injected with circular plasmid DNA did not produce a significant level of antibody against NDV-F, however, two of five birds injected with the linearised plasmid DNA produced high levels of the antibody.
  • a vaccine including a recombinant plasmid nucleic acid sequence, or part thereof, coding for the F protein of a virulent strain of Newcastle disease virus (NDV), or a portion or bioprecursor thereof.
  • NDV Newcastle disease virus
  • the recombinant nucleic acid sequence may comprise plasmid DNA.
  • the recombinant DNA may include plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • the foreign DNA may have a nucleic acid sequence substantially as depicted in annexure A or part thereof.
  • the foreign DNA further may include at least one other gene coding for other proteins or compositions.
  • Said other gene may be selected from the group comprising HN gene, type 1 interferon gene, and interferon -gamma gene.
  • a gene, or part thereof coding for the F protein of a virulent strain of NDV is provided.
  • the gene may have a nucleic acid sequence substantially as depicted in annexure A.
  • recombinant DNA comprising a plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • a DNA molecule having the following terminal sequences: 5':TGGATCCGGT GATGACCAAA GG: 3'.
  • the above DNA molecule may have in the order of 1500 to 2000 base pairs.
  • a genetic vaccine comprising a recombinant DNA molecule including a DNA sequence coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • a recombinant subunit vaccine capable of expressing an F protein of a virulent strain of NDV via a suitable expression system.
  • the invention further relates to the expression of such a recombinant subunit vaccine via any suitable prokaryotic or eukaryotic expression system such as viral-vectored-; yeast-; plant-; mammalian-; fish-; or bacterial expression systems.
  • a suitable prokaryotic or eukaryotic expression system such as viral-vectored-; yeast-; plant-; mammalian-; fish-; or bacterial expression systems.
  • a vaccine comprising a peptide derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • the invention further relates to F protein of a virulent strain of NDV produced by the method described above.
  • the invention further relates to F protein of a virulent strain of NDV as described above as a reagent for use in an assay method for detecting virulent NDV infections.
  • the invention further relates to the use of F protein of a virulent strain of NDV as described above as a vaccine component for eliciting a protective effect in animals against virulent NDV.
  • a diagnostic serotype sequence specific probe derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • the invention further relates to the use of a serotype sequence specific probe as described above in a method of diagnosing virulent NDV in animals.
  • the invention further relates to the use of sequence specific ssDNA oligonucleotides or primers in an amplification based method diagnosing the presence of a virulent NDV in animals.
  • This aspect of the invention may also be applied to differential diagnosis of virulent and non-virulent (or vaccine) virus presence or infection.
  • a method of treatment of virulent NDV including the step of administering to an animal, an effective amount of a vaccine, a genetic vaccine or a recombinant subunit vaccine as hereinbefore described.
  • the vaccine is administered by intra-muscular injection; intra- dermal injection; sub-cutaneous injection; oral immunisation; occular immunisation; in ovo immunisation; and/or by bacterial vector delivery.
  • a strain (Onderstepoort vaccine strain) of the Newcastle disease virus was obtained in 1985 from the Onderstepoort Vaccine Factory (now Onderstepoort Biological Products).
  • RNA Extraction 30ml of infective allantoic fluid was centrifuged at 2000g for 5 min. Supernatant was then centrifuged at 88000g for 1 hour and the virus pellet suspended in 1 ml TNE (1 OmM Tris pH7.4, 10OmM NaCI, 1 mM Na 2 EDTA).
  • cDNA was prepared by incubating 3 ⁇ l RNA, 1.4 ⁇ l 5X RT buffer (Superscript,
  • the tube was then incubated at 37°C for 1hr.
  • reaction was then carried out using a denaturing temperature of 94°C for 30 sec, annealing at 38°C for 1 min and elongation at 72°C for 5 min for 30 cycles.
  • An amplicon obtained using the RT-PCR method described above was selected for cloning into the commercially available pCR-Blunt vector system (Invitrogen). A protocol outlined in the kit was followed in order to obtain potential clones.
  • sequencing of the insert terminal ends was performed using M13 Forward (-40) and Reverse primers. Sequencing was carried out using the standard di-deoxy method developed by Sanger et al. (Sanger F., Nicklen S. and Coulson A.R., 1977, DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467).
  • Vaccines for example: DNA vaccines, recombinant vaccines, subunit vaccines and edible vaccines; and
  • RNA/DNA probing for example: RNA/DNA probing, Elisa and PCR.
  • the DNA sequence may be used in conjunction with one or more other genes, coding for other proteins or compositions, such as the HN gene, type 1 interferon gene, and interferon -gamma gene.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to a circular polynucleotide vaccine, capable of expressing a fusion (F) protein of a virulent strain of Newcastle disease virus (NDV). This invention further relates to recombinant DNA and a gene encoding such F protein, and bioprecursors and products thereof. The gene may be used in conjunction with one or more other genes, coding for other proteins or compositions, such as the HN gene, type 1 interferon gene, and interferon - gamma gene.

Description

Vaccine for Newcastle Disease Virus
INTRODUCTION
This invention relates to a circular polynudeotide vaccine, capable of expressing a fusion (F) protein of a virulent strain of Newcastle disease virus (NDV). This invention further relates to recombinant DNA and a gene encoding such F protein, and bioprecursors and products thereof.
BACKGROUND TO THE INVENTION A known DNA based vaccine is described in: PROTECTION OF CHICKENS FROM NEWCASTLE DISEASE BY VACCINATION WITH A LINEAR PLASMA DNA EXPRESSING THE F PROTEIN OF NEWCASTLE DISEASE VIRUS; Masashi Sakaguchi, Hideki Nakamura, Kengo Sonoda, Fukusaburo Hamada and Kanji Hirai, Vaccine, Volume 14, Number 8, pp 747 - 752, 1996. In this article, a plasmid DNA vaccine is disclosed comprising plasmid DNA expressing the F protein of an avirulent strain of Newcastle disease virus (NDV- F). Birds were infected with either circular or linearised plasmid DNA. The article concludes that birds injected with circular plasmid DNA did not produce a significant level of antibody against NDV-F, however, two of five birds injected with the linearised plasmid DNA produced high levels of the antibody.
A disadvantage of the vaccine described in the above article is that it is not capable of raising satisfactory levels of antibody against virulent NDV-F. OBJECT OF THE INVENTION
It is therefore an object of the invention to provide a vaccine, a DNA sequence, a gene, and products thereof with which the aforesaid disadvantage can be overcome or at least minimised.
SUMMARY OF THE INVENTION
According to a first aspect of the invention there is provided a vaccine including a recombinant plasmid nucleic acid sequence, or part thereof, coding for the F protein of a virulent strain of Newcastle disease virus (NDV), or a portion or bioprecursor thereof.
The recombinant nucleic acid sequence may comprise plasmid DNA.
The recombinant DNA may include plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
The foreign DNA may have a nucleic acid sequence substantially as depicted in annexure A or part thereof.
The foreign DNA further may include at least one other gene coding for other proteins or compositions. Said other gene may be selected from the group comprising HN gene, type 1 interferon gene, and interferon -gamma gene. According to a second aspect of the invention there is provided a gene, or part thereof coding for the F protein of a virulent strain of NDV.
The gene may have a nucleic acid sequence substantially as depicted in annexure A.
According to another aspect of the invention there is provided recombinant DNA comprising a plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
According to another aspect of the invention there is provided a DNA molecule having the following terminal sequences: 5':TGGATCCGGT GATGACCAAA GG: 3'.
The above DNA molecule may have in the order of 1500 to 2000 base pairs.
According to another aspect of the invention there is provided a genetic vaccine comprising a recombinant DNA molecule including a DNA sequence coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV. According to another aspect of the invention there is provided a recombinant subunit vaccine capable of expressing an F protein of a virulent strain of NDV via a suitable expression system.
The invention further relates to the expression of such a recombinant subunit vaccine via any suitable prokaryotic or eukaryotic expression system such as viral-vectored-; yeast-; plant-; mammalian-; fish-; or bacterial expression systems.
According to another aspect of the invention there is provided a vaccine comprising a peptide derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
According to another aspect of the invention there is provided a method of producing F protein of a virulent strain of NDV by expression of a recombinant DNA molecule via a suitable expression system.
The invention further relates to F protein of a virulent strain of NDV produced by the method described above.
The invention further relates to F protein of a virulent strain of NDV as described above as a reagent for use in an assay method for detecting virulent NDV infections. The invention further relates to the use of F protein of a virulent strain of NDV as described above as a vaccine component for eliciting a protective effect in animals against virulent NDV.
According to another aspect of the invention there is provided a diagnostic serotype sequence specific probe derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
The invention further relates to the use of a serotype sequence specific probe as described above in a method of diagnosing virulent NDV in animals.
The invention further relates to the use of sequence specific ssDNA oligonucleotides or primers in an amplification based method diagnosing the presence of a virulent NDV in animals. This aspect of the invention may also be applied to differential diagnosis of virulent and non-virulent (or vaccine) virus presence or infection.
According to another aspect of the invention there is provided a method of treatment of virulent NDV including the step of administering to an animal, an effective amount of a vaccine, a genetic vaccine or a recombinant subunit vaccine as hereinbefore described. Preferably the vaccine is administered by intra-muscular injection; intra- dermal injection; sub-cutaneous injection; oral immunisation; occular immunisation; in ovo immunisation; and/or by bacterial vector delivery.
According to another aspect of the invention there is provided a method of diagnosing or detecting virulent NDV in animals using a serotype specific probe as described above, a recombinant DNA molecule or expression products thereof.
THE INVENTION WILL NOW BE DESCRIBED IN MORE DETAIL BY WAY OF A NON-LIMITING EXAMPLE.
Introduction:
A strain (Onderstepoort vaccine strain) of the Newcastle disease virus was obtained in 1985 from the Onderstepoort Vaccine Factory (now Onderstepoort Biological Products).
Virus Isolation:
30ml of infective allantoic fluid was centrifuged at 2000g for 5 min. Supernatant was then centrifuged at 88000g for 1 hour and the virus pellet suspended in 1 ml TNE (1 OmM Tris pH7.4, 10OmM NaCI, 1 mM Na2EDTA). RNA Extraction:
RNA was extracted using a similar method as previously described (M.S. Collins, J.B. Bashiruddin and D.J. Alexander. Deduced amino acid sequences at the fusion protein cleavage site of Newcastle disease viruses showing variation in antigenicity and pathogenicity. Arch. Virol., 1993, 128:363-370). 10μl proteinase K (10mg/ml) was added to 300μl resuspended virus and
incubated at room temperature for 10 min. before adding 10μl sodium
dodecylsulphate (10% w/v) and incubating at 56°C for 20 min. A phenol/chlorophorm (24:1 v/v) extraction was then performed as described in Sambrook et al. (Sambrook J., Fritsch E.F., Maniatis T., Molecular cloning, a laboratory manual, 2nd edition. Cold Spring Harbour Press, New York, 1989.) The aqueous phase was removed to a new tube, and RNA precipitated using 0.3M Sodium acetate and 2 volumes of 96% ethanol. The RNA was allowed to precipitate at -20°C overnight. After centrifugation, pellets were washed in 70% RNase-free ice-cold ethanol and centrifuged once more. RNA pellets were
allowed to dry at room temperature for 15 min before resuspending in 15μl
RNase-free water at 65°C for 5 min.
Accession Numbers for sequences of NDV strains used in alignments for primer design: M24692 M21881 M24694 M24695 M24696
RT-PCR :
cDNA was prepared by incubating 3μl RNA, 1.4μl 5X RT buffer (Superscript,
Gibco BRL), 1μl (50μM) Primer NDV-5 (5'-TGGATCCCGGTTGGCGC-3') and
1.8μl nuclease-free water at 100°C for 30 seconds, and then at 37°C for 10
min. To this was added, 0.7μl HPRI (100u/μl, Amersham) , 0.6μl 5X RT buffer
(Superscript, Gibco BRL), 0.5μl dNTP mix (2.5mM dATP, dUTP, dTTP, dCTP),
0.5μl water and 0.5μl reverse transcriptase (Superscript 200u/μl, Gibco BRL).
The tube was then incubated at 37°C for 1hr.
A PCR reaction was performed on freshly synthesized cDNA using standard
methods. 5μl cDNA was added to a tube containing 0.5μl Takara ExTaq
polymerase (5 u/μl), 10μl 10X ExTaq buffer (Takara), 8μl dNTP mix (2.5mM
dATP, dTTP, dCTP, dGTP), 1μl primer NDV-5 (50μM), 1 μl (50μM) primer NDV-
6 (5'-CCTTTGGTCATCTACA-3') and 75μl nuclease-free water. A PCR
reaction was then carried out using a denaturing temperature of 94°C for 30 sec, annealing at 38°C for 1 min and elongation at 72°C for 5 min for 30 cycles.
Typically 10μl of the PCR mix was then analysed using agarose gel
electrophoresis to ensure that a fragment of the predicted size had been amplified. Cloning PCR Products:
An amplicon obtained using the RT-PCR method described above was selected for cloning into the commercially available pCR-Blunt vector system (Invitrogen). A protocol outlined in the kit was followed in order to obtain potential clones.
Sequencing and Analysis:
In order to identify which clones contained the desired NDV-F protein ORF and to ascertain directionality of the insert in the plasmid, sequencing of the insert terminal ends was performed using M13 Forward (-40) and Reverse primers. Sequencing was carried out using the standard di-deoxy method developed by Sanger et al. (Sanger F., Nicklen S. and Coulson A.R., 1977, DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467).
In order to sequence the entire NDV-F protein it was first necessary to construct 2 subclones from the original open reading frame in pUC19 using the restriction enzymes Xmal and EcoRI. These subclones were then sequenced by automated sequencing using the standard M13 Forward (-40) and Reverse primers. All sequence data obtained was confirmed by sequencing the subclones in both the forward and reverse orientations.
The sequence of the gene is depicted in the annexed sequence listing. Application:
The applicant foresees that this invention have application in inter alia the following: - Vaccines, for example: DNA vaccines, recombinant vaccines, subunit vaccines and edible vaccines; and
Diagnostics, for example: RNA/DNA probing, Elisa and PCR.
It will be appreciated that variations in detail are possible with a vaccine, a DNA sequence, a gene, and products thereof according to the invention without departing from the scope of the appended claims. For example, the DNA sequence may be used in conjunction with one or more other genes, coding for other proteins or compositions, such as the HN gene, type 1 interferon gene, and interferon -gamma gene.

Claims

1. A vaccine including a recombinant plasmid nucleic acid sequence, or part thereof, coding for the F protein of a virulent strain of Newcastle disease virus (NDV), or a portion or bioprecursor thereof.
2. A vaccine according to claim 1 wherein the recombinant nucleic acid sequence comprises plasmid DNA.
3. A vaccine according to claim 2 wherein the recombinant DNA includes plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
4. A vaccine according to claim 3 wherein the foreign DNA has a nucleic acid sequence substantially as depicted in annexure A or part thereof.
5. A vaccine according to claim 4 wherein the foreign DNA further includes at least one other gene coding for other proteins or compositions.
6. A vaccine according to claim 5 wherein said other gene is selected from the group comprising HN gene, type 1 interferon gene, and interferon -
gamma gene.
7. A gene, or part thereof coding for the F protein of a virulent strain of NDV.
8. A gene, or part thereof having a nucleic acid sequence substantially as depicted in annexure A.
9. Recombinant DNA comprising a plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
10. A DNA molecule having the following terminal sequences: 5':TGGATCCGGT GATGACCAAA GG: 3'.
11. A DNA molecule according to claim 10 which have in the order of 1500 to 2000 base pairs.
12. A genetic vaccine comprising a recombinant DNA molecule including a DNA sequence coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
13. A recombinant subunit vaccine capable of expressing an F protein of a virulent strain of NDV via a suitable expression system.
14. A recombinant subunit vaccine according to claim 13 which is expressed via an expression system selected from the group comprising: prokaryotic expression system; eukaryotic expression system; viral- vectored-; yeast-; plant-; mammalian-; fish-; and bacterial expression systems.
15. A vaccine comprising a peptide derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
16. A method of producing an F protein of a virulent strain of NDV by expression of a recombinant DNA molecule via a suitable expression system.
17. F protein of a virulent strain of NDV produced by the method of claim 16.
18. A reagent for use in an assay method for detecting virulent NDV infections comprising F protein according to claim 17.
19. A vaccine component for eliciting a protective effect in animals against virulent NDV comprising F protein according to claim 17.
20. A diagnostic serotype sequence specific probe derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
21. Use of the serotype sequence specific probe of claim 20 in a method of diagnosing virulent NDV in animals.
22. Use of sequence specific ssDNA oligonucleotides or primers in an amplification based method for diagnosing the presence of a virulent NDV in animals.
23. A method for treatment of virulent NDV including the step of administering to an animal an effective amount of a vaccine according to any one of claims 1 to 6, and 15
24. A method for treatment of virulent NDV including the step of administering to an animal an effective amount of a genetic vaccine according of claim 12.
25. A method for treatment of virulent NDV including the step of administering to an animal an effective amount of a recombinant subunit vaccine according to any one of claims 13 and 14.
26. A method according to any one of claims 23 to 25 wherein the vaccine is administered by a method selected form the group comprising: intramuscular injection; intra-dermal injection; sub-cutaneous injection; oral immunisation; occular immunisation; in ovo immunisation; and bacterial vector delivery.
27. A method of diagnosing or detecting virulent NDV in animals using a serotype specific probe according to claim 20, a recombinant DNA molecule or expression products thereof.
28. A vaccine substantially as herein described and exemplified.
29. A gene, or part thereof substantially as herein described and exemplified.
30. Recombinant DNA substantially as herein described and exemplified.
31. A DNA molecule substantially as herein described and exemplified.
32. A genetic vaccine substantially as herein described and exemplified.
33. A recombinant subunit vaccine substantially as herein described and exemplified.
34. A method of producing an F protein of a virulent strain of NDV substantially as herein described and exemplified.
35. F protein of a virulent strain of NDV substantially as herein described and exemplified.
36. A diagnostic serotype sequence specific probe substantially as herein described and exemplified.
37. A method of treatment of virulent NDV substantially as herein described and exemplified.
38. A method of diagnosing or detecting virulent NDV in animals substantially as herein described and exemplified.
PCT/IB2000/000748 1999-06-10 2000-06-05 Vaccine for newcastle disease virus Ceased WO2000077218A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46060/00A AU4606000A (en) 1999-06-10 2000-06-05 Vaccine for newcastle disease virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA99/3896 1999-06-10
ZA993896 1999-06-10

Publications (1)

Publication Number Publication Date
WO2000077218A1 true WO2000077218A1 (en) 2000-12-21

Family

ID=25587769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000748 Ceased WO2000077218A1 (en) 1999-06-10 2000-06-05 Vaccine for newcastle disease virus

Country Status (2)

Country Link
AU (1) AU4606000A (en)
WO (1) WO2000077218A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454870B1 (en) * 2001-07-30 2004-11-03 주식회사 인트론바이오테크놀로지 F protein and HN protein of Newcastle disease virus strains and genes thereof
CN1293195C (en) * 2005-09-02 2007-01-03 中国农业科学院哈尔滨兽医研究所 Reverse genetic operation system of New castle disease LaSota vaccine strain and its applciation
CN102716478A (en) * 2012-06-26 2012-10-10 普莱柯生物工程股份有限公司 Combined Newcastle disease and infectious bronchitis inactivated vaccine and method for preparing same
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774373B (en) * 2022-04-27 2024-07-05 北京市农林科学院 Carrier pigeon newcastle disease virus genetic engineering attenuated strain and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227414A2 (en) * 1985-12-18 1987-07-01 Btg International Limited Newcastle disease virus gene clones
EP0252060A1 (en) * 1986-06-30 1988-01-07 Smithkline Beckman - Animal Health Products DNA sequence, recombinant DNA molecules, and method for the production of the Newcastle disease virus fusion protein or equivalent polypeptides, products obtained and preparations containing them
WO1996012808A1 (en) * 1994-10-20 1996-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Nucleic acid preparation for immunization and method for immunization using the same
FR2751225A1 (en) * 1996-07-19 1998-01-23 Rhone Merieux AVIAN POLYNUCLEOTIDE VACCINE FORMULA

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227414A2 (en) * 1985-12-18 1987-07-01 Btg International Limited Newcastle disease virus gene clones
EP0252060A1 (en) * 1986-06-30 1988-01-07 Smithkline Beckman - Animal Health Products DNA sequence, recombinant DNA molecules, and method for the production of the Newcastle disease virus fusion protein or equivalent polypeptides, products obtained and preparations containing them
WO1996012808A1 (en) * 1994-10-20 1996-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Nucleic acid preparation for immunization and method for immunization using the same
FR2751225A1 (en) * 1996-07-19 1998-01-23 Rhone Merieux AVIAN POLYNUCLEOTIDE VACCINE FORMULA

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANT, A. ET AL.: "Differentiation of virulent and non-virulent strains of Newcastle disease virus within 24 hours by polymerase chain reaction", AVIAN PATHOLOGY, vol. 26, December 1997 (1997-12-01), pages 837 - 849, XP000960911 *
NAOHIRO, K. ET AL.: "Protective effect of individual glycoproteins of Newcastle disease virus expressed in insect cells: The fusion protein derived from an avirulent strain had lower protective efficacy.", VIRUS RESEARCH, vol. 32, 1994, pages 373 - 379, XP000960765 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454870B1 (en) * 2001-07-30 2004-11-03 주식회사 인트론바이오테크놀로지 F protein and HN protein of Newcastle disease virus strains and genes thereof
CN1293195C (en) * 2005-09-02 2007-01-03 中国农业科学院哈尔滨兽医研究所 Reverse genetic operation system of New castle disease LaSota vaccine strain and its applciation
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
CN102716478A (en) * 2012-06-26 2012-10-10 普莱柯生物工程股份有限公司 Combined Newcastle disease and infectious bronchitis inactivated vaccine and method for preparing same

Also Published As

Publication number Publication date
AU4606000A (en) 2001-01-02

Similar Documents

Publication Publication Date Title
US20240100151A1 (en) Variant strain-based coronavirus vaccines
JP2534246B2 (en) Newcastle disease virus gene clone
Lopez et al. The L protein of Rift Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic genome-like RNA molecules
EP0490972B2 (en) Recombinant negative strand rna virus expression systems and vaccines
Kraatz et al. Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge
US8647637B2 (en) Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
ES2588225T3 (en) Nucleic acid sequences of a fish virus and their use
JP2010259445A (en) Attenuated pestivirus
KR19990022335A (en) Novel recombinant thermophilic mutants of influenza
Vennema et al. Genomic organization and expression of the 3′ end of the canine and feline enteric coronaviruses
JP2009529861A (en) Recombinant Newcastle disease virus expressing avian influenza virus H5 hemagglutinin
CN112063592A (en) Construction of an attenuated strain with combined deletion of multiple genes in African swine fever and its application as a vaccine
CN101563361A (en) Influenza viruses capable of infecting canines and uses thereof
CN113293145A (en) New measles virus live vector corona vaccine
de Swart et al. Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines
US6231863B1 (en) DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
US20230029979A1 (en) Broadly protective bovine parainfluenza 3 virus and bovine viral diarrhea virus vaccine
EP3894429B1 (en) Crimean-congo hemorrhagic fever virus replicon particles and use thereof
US20100028384A1 (en) Yeast expressed classical swine fever virus glycoprotein e2 and use thereof
JP4691495B2 (en) Coronavirus spike S1 fusion protein and expression vector thereof
WO2000077218A1 (en) Vaccine for newcastle disease virus
Ling et al. Sequence and in vitro expression of the phosphoprotein gene of avian pneumovirus
TW202309290A (en) Deoptimized sars-cov-2 variants and methods and uses thereof
US20240226258A1 (en) In-vitro transcript mrna and pharmaceutical composition comprising same
Kanno et al. The complete nucleotide sequence of the PanAsia strain of foot-and-mouth disease virus isolated in Japan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200109150

Country of ref document: ZA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP